ArticleClinical epigenetics2026
ATAD2 suppresses senescence and SASP via SIRT7-p53/p21 to drive progression and immune evasion in endometrial cancer.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEndometrial cancer is one of the gynecological malignancies, currently ranking first in mortality among the three major gynecological cancers. Effective treatment options remain scarce. ATAD2, a chromatin remodeler, is implicated in solid tumor progression, but its role in endometrial cancer (EC) and tumor microenvironment (TME) remodeling remains unclear. This study investigated the functional impact and mechanisms of ATAD2 in EC pathogenesis.
methodsBased on the publicly available TCGA Uterine Corpus Endometrioid Carcinoma (UCEC) dataset, we preliminarily clarified the pro-cancer role of ATAD2. To explore its mechanism, this study constructed EC cell lines with stable ATAD2 overexpression and knockdown, and assessed cell proliferation, migration, and invasion capabilities; combined with bioinformatics analysis, we screened potential regulatory pathways. We verified the interaction between ATAD2 and SIRT7 protein using immunoprecipitation, molecular docking, GST-pull-down, and proximity ligation (PLA) techniques. Flow cytometry was used to detect macrophage polarization status, SA-β-galactosidase activity and p53/p21 expression levels were used to assess cellular senescence, and enzyme-linked immunosorbent assay (ELISA) was used to quantitatively analyze senescence-related secreted phenotypic factors. Furthermore, through immune cell infiltration atlas analysis and combined with a xenograft tumor model, we evaluated the in vivo antitumor effect of the ATAD2 inhibitor BAY-850.
resultsHigh ATAD2 expression correlated with poor EC prognosis and enhanced cancer cell proliferation, migration, and invasion. Mechanistic studies have shown that ATAD2 interacts directly with SIRT7 through its bromine domain and enhances its protein stability. SIRT7 regulates p21 transcription by deacetylation of the lysine K382 site of p53 protein, thereby inhibiting cell senescence and SASP secretion.High ATAD2 expression was linked to increased TP53 mutation burden and suppressed anti-tumor immunity. ATAD2 inhibition promotes SASP secretion and induces M1 macrophage polarization, an effect that can be reversed by SIRT7 upregulation. BAY-850 inhibits tumor growth and metastasis in vivo.
conclusionATAD2 suppresses cellular senescence and SASP phenotypes via the SIRT7-p53/p21 axis, promoting immune-suppressive TME and driving EC progression and immune evasion. ATAD2 represents a promising therapeutic target for EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.